Share-based Payment Arrangement, Expense of Tempest Therapeutics, Inc. from 30 Sep 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Tempest Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2011 to 30 Sep 2025.
  • Tempest Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $61,000, a 95% decline year-over-year.
  • Tempest Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,873,000, a 24% decline year-over-year.
  • Tempest Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,303,000, a 108% increase from 2023.
  • Tempest Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,546,000, a 63% increase from 2022.
  • Tempest Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1,561,000, a 41% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Tempest Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,873,000 $61,000 -$1,273,000 -95% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $5,146,000 $1,092,000 -$228,000 -17% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $5,374,000 $1,389,000 +$71,000 +5.4% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $5,303,000 $1,331,000 +$234,000 +21% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $5,069,000 $1,334,000 +$771,000 +137% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $4,298,000 $1,320,000 +$880,000 +200% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $3,418,000 $1,318,000 +$872,000 +196% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $2,546,000 $1,097,000 +$669,000 +156% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $1,877,000 $563,000 +$125,000 +29% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $1,752,000 $440,000 +$73,000 +20% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $1,679,000 $446,000 +$118,000 +36% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $1,561,000 $428,000 +$150,000 +54% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
Q3 2022 $1,411,000 $438,000 +$142,000 +48% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $1,269,000 $367,000 -$44,000 -11% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $1,313,000 $328,000 +$208,000 +173% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $1,105,000 $278,000 +$1,223,000 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $118,000 $296,000 +$205,000 +225% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $323,000 $411,000 +$184,000 +81% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $507,000 $120,000 -$960,000 -89% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q4 2020 $453,000 $945,000 -$2,133,000 -180% 01 Oct 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
Q3 2020 $2,586,000 $91,000 -$1,105,000 -92% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $3,691,000 $227,000 -$767,000 -77% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $4,458,000 $1,080,000 +$141,000 +15% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $4,317,000 $1,188,000 +$520,000 +78% 01 Oct 2019 31 Dec 2019 10-K 29 Mar 2021 2020 FY
Q3 2019 $3,797,000 $1,196,000 +$773,000 +183% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $3,024,000 $994,000 +$835,000 +525% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $2,189,000 $939,000 +$762,000 +431% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q4 2018 $1,427,000 $668,000 01 Oct 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
Q3 2018 $423,000 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2019 Q3
Q2 2018 $159,000 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019 2019 Q2
Q1 2018 $177,000 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
Q3 2013 $200,000 -$100,000 -33% 01 Jul 2013 30 Sep 2013 10-Q 13 Nov 2013 2013 Q3
Q3 2012 $300,000 +$270,000 +900% 01 Jul 2012 30 Sep 2012 10-Q 13 Nov 2012 2012 Q3
Q2 2012 $299,100 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2012 2012 Q2
Q3 2011 $30,000 01 Jul 2011 30 Sep 2011 10-Q 13 Nov 2012 2012 Q3

Tempest Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,303,000 +$2,757,000 +108% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $2,546,000 +$985,000 +63% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $1,561,000 +$456,000 +41% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $1,105,000 +$652,000 +144% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $453,000 -$3,864,000 -90% 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
2019 $4,317,000 +$2,890,000 +203% 01 Jan 2019 31 Dec 2019 10-K 29 Mar 2021 2020 FY
2018 $1,427,000 +$665,000 +87% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
2017 $762,000 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.